Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)
Industry: Healthcare

Listed 2 Consecutive Market Days. On List as of 07/14/2008 Through 07/16/2008

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Current Quote*
Last: $4.065
Change: 0.000
Book: $0.992
Volume: 106,889

As Of: 02/13 13:07 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol THRX

  • No BuyIns.Net Alerts Available for THRX

Graphs for THRX


3 Month Graph


6 Month Graph


1 Year Graph